Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
EvaluatePharma
Evaluate Omnium
Japan Drug Forecasts
European Drug Forecasts
Epi Analyzer
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
YM BioSciences
September 22, 2016
Bubble stocks top the takeover premium charts
September 07, 2016
How Gilead could go back to basics
December 17, 2015
Galapagos turns the tables on AbbVie, courtesy of Gilead
May 07, 2015
Gilead deal shows desire to put oncology at centre of post-Hep C strategy
January 24, 2014
Deal metrics climb in 2013 but big pharma stays away from M&A
October 01, 2013
Therapeutic focus – New agents nip at Jakafi’s heels in myelofibrosis
December 12, 2012
Gilead hopes acquisition JAKs up oncology pipeline
February 27, 2012
YM ready for long haul with myelofibrosis candidate
December 14, 2011
YM gets boost out of ASH results
October 06, 2011
Therapeutic Focus - Poor progress in pancreatic cancer
January 04, 2011
Deals and financing over the Christmas period
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
July 29, 2020
Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020
April 16, 2020
Evaluate Vantage COVID-19 Report
Editor's Picks
October 20, 2020
Finding the next Vertex
October 15, 2020
Clinical setback lays bare Vertex’s weakness
October 15, 2020
SITC 2020 – embargo snafu triggers the first movers
October 19, 2020
Biopharma buyouts still pricey
September 30, 2020
More biotechs test the third way to market
